Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05362474 · ClinicalTrials.gov registry record · Phase 3
Targeting Leukotrienes in Kidney Disease
A Phase 3 study, sponsored by University of Colorado, Denver.
- Terminated
- Registry status
- Phase 3
- Development phase
- 6
- Enrollment target
NCT05362474: Clinical Trial Phase 3 study, sponsored by University of Colorado, Denver.
NCT05362474 is a Phase 3 study that was terminated before completion, run by University of Colorado, Denver. The registered enrollment target is 6 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05362474, a Phase 3 study, was terminated before completion, sponsored by University of Colorado, Denver.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 6 participants
- Enrollment target
Study Summary
Diabetic kidney disease (DKD) is associated with significant morbidity and mortality. Identifying new treatments for DKD to be used alone or in combination with other therapies is a high priority. Inflammation plays a key role in DKD and targeting pro-inflammatory lipid mediators called leukotrienes may represent a promising therapy for DKD. The current proposal will investigate whether montelukast, a leukotriene antagonist, reduces proteinuria and improves vascular function and arterial stiffness in patients with DKD.
Primary Outcome
Change in 24-hour urine albumin excretion at 3 months
Interventions
- DRUG Montelukast
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2022-07-01 |
| Est. Completion | 2023-06-20 |
| Phase | Phase 3 |
Why NCT05362474 stopped before completion
NCT05362474 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which Montelukast is the first listed.
NCT05362474 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05362474 about?
NCT05362474 is a clinical study titled "Targeting Leukotrienes in Kidney Disease". Diabetic kidney disease (DKD) is associated with significant morbidity and mortality. Identifying new treatments for DKD to be used alone or in combination with other therapies is a high priority. Inflammation plays a key role in DKD and targeting pro-inflammatory lipid mediators called leukotrienes...
What is the current status of trial NCT05362474?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 6 participants. The study started on 2022-07-01. Estimated completion is 2023-06-20.
What interventions are being tested in trial NCT05362474?
The interventions under investigation include: Montelukast (DRUG).
Who is sponsoring clinical trial NCT05362474?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05362474's enrollment target sits among peer trials
6 1995th of 2000 higher than 4 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI